There are currently 26 active clinical trials seeking participants for Interstitial Lung Disease research studies. The states with the highest number of trials for Autism participants are California, Texas, Florida and New York.
Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)
NCT05892614
Recruiting
This is a double-blind, randomized, placebo-controlled, PoC study to evaluate the efficacy, safety, and tolerability of efzofitimod in patients with SSc-ILD. The primary objective of the study is to evaluate the PoC for efficacy in a population with SSc-ILD. While improvement of ILD is the outcome of interest, the study will also evaluate changes in the skin. After initial screening (up to 4 weeks), approximately 25 eligible participants will be randomized 2:2:1 to 1 of 2 active (experimental) d... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/19/2024
Locations: aTyr Investigative Site, Los Angeles, California +14 locations
Conditions: Interstitial Lung Disease
Register for Updates
Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)
NCT05943535
Recruiting
Study RIN-PF-305 is designed to evaluate the safety and efficacy of inhaled treprostinil in subjects with progressive pulmonary fibrosis (PPF) over a 52-week period.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/17/2024
Locations: UAB Lung Health Center, Birmingham, Alabama +29 locations
Conditions: Progressive Pulmonary Fibrosis, Interstitial Lung Disease
Register for Updates
Pulmonary Hypertension Screening in Patients With Interstitial Lung Disease for Earlier Detection
NCT05776225
Recruiting
Study GMS-PH-001 is a multicenter, open-label, non-randomized study to prospectively evaluate screening strategies of pulmonary hypertension (PH) in patients with interstitial lung disease (ILD).
Gender:
All
Ages:
18 years and above
Trial Updated:
04/15/2024
Locations: Pulmonary Associates, Phoenix, Arizona +18 locations
Conditions: Interstitial Lung Disease, Pulmonary Hypertension
Register for Updates
Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)
NCT05270668
Recruiting
The purpose of this study is to assess the safety and efficacy of tulisokibart in participants with SSc-ILD.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/04/2024
Locations: Mayo Clinic - Scottsdale ( Site 4014), Phoenix, Arizona +73 locations
Conditions: Diffuse Cutaneous Systemic Sclerosis, Interstitial Lung Disease
Register for Updates
Efficacy of Two Doses of Duloxetine & Amitriptyline in Interstitial Lung Disease-related Cough
NCT05120934
Recruiting
This research study is evaluating the effectiveness of escalating doses of Amitriptyline and Duloxetine in reducing cough frequency in patients with interstitial lung disease (ILD)-related cough.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
03/29/2024
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Interstitial Lung Disease
Register for Updates
Creation of a Biospecimen Repository From Patients With Interstitial Lung Diseases (ILD)
NCT03478826
Recruiting
To develop a repository of blood samples from patients with ILD to support future studies into the development of such biomarkers. Patients with pneumonia and healthy patients will also be recruited as a control group.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/21/2024
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Interstitial Lung Disease
Register for Updates
Abatacept for the Treatment of Common Variable Immunodeficiency With Interstitial Lung Disease
NCT04925375
Recruiting
There is no standard of care therapy for patients with granulomatous-lymphocytic interstitial lung disease (GLILD) seen in common variable immunodeficiency (CVID). Abatacept has recently looked promising for the treatment of patients with complex CVID. This study is a multi-site, phase II, randomized, blinded/placebo-controlled clinical trial in pediatric and adult subjects to determine the efficacy of abatacept compared to placebo for treatment of subjects with GLILD in the context of CVID. Fu... Read More
Gender:
All
Ages:
4 years and above
Trial Updated:
03/13/2024
Locations: University of California, San Francisco, San Francisco, California +5 locations
Conditions: Interstitial Lung Disease, Common Variable Immunodeficiency
Register for Updates
Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis
NCT04708782
Recruiting
Study RIN-PF-301 is designed to evaluate the superiority of inhaled treprostinil against placebo for the change in absolute forced vital capacity (FVC) from baseline to Week 52.
Gender:
All
Ages:
40 years and above
Trial Updated:
03/01/2024
Locations: The University of Alabama at Birmingham, Birmingham, Alabama +98 locations
Conditions: Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease
Register for Updates
129Xe MRI Cardiopulmonary
NCT06038630
Recruiting
The goal of this NIH-sponsored study is to characterize three biomarkers derived from 129Xe gas exchange MRI and to understand how they change in response to interventions.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/19/2024
Locations: Duke University Medical Center, Durham, North Carolina
Conditions: Interstitial Lung Disease, Chronic Thromboembolic Pulmonary Hypertension, Acute Pulmonary Embolism, Anemia, Polycythemia, Dyspnea
Register for Updates
An Open-Label ProSpective MultiCENTer Study to Evaluate Safety and Tolerability of Dry Powder Inhaled Treprostinil in PH
NCT06129240
Recruiting
Study LTI-401 is an open-label, multicenter study which will evaluate the safety and tolerability of LIQ861 in subjects who have WHO Group 1 & 3 PH.
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
01/30/2024
Locations: Arizona Pulmonary Specialists, Phoenix, Arizona +2 locations
Conditions: Pulmonary Hypertension, Interstitial Lung Disease
Register for Updates
Feasibility of Semaglutide in Advanced Lung Disease
NCT05746039
Recruiting
The goal of this clinical trial is to learn whether semaglutide, an FDA-approved treatment for diabetes and obesity, is feasible and tolerable in patients with advanced lung disease. The main question[s] it aims to answer are: Are patients with advanced lung disease able to tolerate semaglutide therapy? Are we able to titrate semaglutide therapy to a target weight? Participants will be asked to perform pulmonary function, physical function and body composition testing, as well as a blood draw... Read More
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
01/29/2024
Locations: University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania
Conditions: Obesity, Interstitial Lung Disease, Chronic Obstructive Pulmonary Disease, Sarcoidosis, Pulmonary, Pulmonary Hypertension
Register for Updates
Collagen-targeted PET Imaging for Early Interstitial Lung Disease
NCT05417776
Recruiting
The goal of this study is to investigate the ability of [68Ga]CBP8 to detect collagen deposition in early interstitial lung disease.
Gender:
All
Ages:
40 years and above
Trial Updated:
01/24/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Interstitial Lung Disease
Register for Updates